Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro))
Specificity
Detects C3b deposits in tissue, on cells, on microorganisms and in immune complexes. Does not react with C3a or C3d. Inhibits hemolytic function of C3. It should be used with positive control anti C3b-α (clone H206, cat.no. BM5029), and negative control anti C3a (clone H13, cat.no. BM2131). Activated, deposited C3b bears 3b-α and -ß, but no longer C3a. Ubiquitous or nonspecifically absorbed C3 is still C3a positive with clone H13.
C3
Reactivity: Human
WB, ELISA
Host: Mouse
Polyclonal
unconjugated
Application Notes
Western Blot. Immunohistochemistry on frozen tissue (Dilution 1: 10, Incubation time: 1h at RT). Successful use on paraffin embedded tissue was reported by some researchers. As thisdetection method has not been verified by antibodies-online, the application was deletedfrom the database. This does not necessarily exclude the use in such procedure. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
The complement factor C3 consists of an alpha and a beta chain. C3 is a central factor in the complement cascade. It is central to the alternative pathway that leads to the C3 convertase C3bBb. The classical mannose binding lectin activation pathway leads to the C3 convertase C4b2a. These convertases cleave C3 resulting in C3a and C3b. Further degradation leads to the formation of the alpha chain products C3d, C3g and C3c. C3 is an acute phase protein that is produced by a wide range of tissues, including renal epithelial cells and hepatocytes.Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, CPAMD1, Complement component 3